BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving research platform. New compounds and evidence are added continuously.
B

Mylabris Phalerata

37+ PubMed studies analyzed · Evidence Score: 24.3

Research Domains

Mylabris Phalerata has been studied across 10 research domains including 🔬 Oncology, ⚡ Energy & Fatigue, 🫁 Liver & Detox, 🧠 Focus & Attention, ⏳ Longevity & Aging. The primary research focus is 🔬 Oncology with 46% of studies addressing this area.

Traditional Use (Ayurveda)

Known as banmao / 斑蝥 in Ayurveda. Karma (actions): Treats cold-heat alternation, Expels ghost-possession and gu toxin, Treats rat sores [UNTRANSLATED: 鼠], Resolves malignant sores and ju abscess, Erodes dead muscle, Breaks stone strangury, Treats scabies and tinea, Induces abortion, Treats scrofula, Promotes water passage, Treats strangury diseases, Applies topically to malignant sores with ulceration, Treats hernia and abdominal masses, Resolves ding toxin, mad-dog bite toxin, sha louse toxin, and gu toxin.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Mylabris Phalerata, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

lithospermum
2119 shared targets
curculigo
1870 shared targets
Foeniculum
2180 shared targets
quisqualis
2233 shared targets
anemarrhena
1869 shared targets
cnidium
1859 shared targets
morinda
2396 shared targets
allium
2051 shared targets
prunus
2161 shared targets
scrophularia
2149 shared targets
Loading evidence profile...

This evidence profile for Mylabris Phalerata is generated deterministically from 37 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.